Litigation Details for POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (D.N.J. 2015)

POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (D.N.J. 2015)

Docket	3:15-cv-07658	Date Filed	2015-10-22
Court	District Court, D. New Jersey	Date Terminated	2025-04-22
Cause	15:78m(a) Securities Exchange Act	Assigned To	Michael Andre Shipp
Jury Demand	Both	Referred To	Rukhsanah L. Singh
Parties	BLACKROCK SHORT DURATION HIGH INCOME FUND; LORD ABBETT INVESTMENT TRUST-LORD ABBETT HIGH YIELD FUND
Patents	6,861,053; 7,045,620; 7,452,857; 7,605,240; 7,612,199; 7,902,206; 7,906,542; 7,915,275; 8,158,644; 8,158,781; 8,193,196; 8,309,569; 8,518,949; 8,642,573; 8,741,904; 8,829,017; 8,835,452; 8,853,231; 8,946,252; 8,969,398
Attorneys	BRANDON MICHAEL FIERRO; MICHAEL JAMES GESUALDO
Firms	Chiesa Shahinian & Giantomasi PC; Kirby McInerney LLP
Link to Docket	External link to docket

Details for POTTER v. VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (D.N.J. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-22				External link to document
2015-10-22	167	Exhibit 31-48	Patent No. 6,861,053 (the “‘053 patent”), U.S. Patent No. 7,452,857 (the “‘857 patent”), U.S. Patent No. 7,…620 patent, the ‘199 patent, the ‘206 patent, the ‘542 patent, the ‘275 patent, the ‘644 patent, the…of the ‘569 patent, the ‘573 patent, the ‘017 patent, the ‘252 patent and the ‘398 patent. Alfa Wassermann…the ‘781 patent, the ‘196 patent, the ‘949 patent, the ‘904 patent, the ‘452 patent and the ‘231 patent…of the ‘053 patent, the ‘857 patent, the ‘240 patent, the ‘608 patent and the ‘799 patent , each of which	External link to document

Potter v. Valeant Pharmaceuticals International, Inc. Litigation Summary and Analysis, Case No. 3:15-cv-07658

Last updated: August 2, 2026

Potter v. Valeant Pharmaceuticals International, Inc., No. 3:15-cv-07658, was a U.S. securities-fraud class action filed in the District of New Jersey after Valeant Pharmaceuticals’ stock price collapsed in 2015. The case concerned alleged misrepresentations about Valeant’s revenue recognition, drug-pricing practices, specialty-pharmacy relationship with Philidor Rx Services, accounting controls, and business performance.

The action was later consolidated with related securities cases as In re Valeant Pharmaceuticals International, Inc. Securities Litigation. The litigation ultimately produced a reported settlement of approximately $1.21 billion, subject to court approval and allocation among eligible class members. The case is a securities and corporate-disclosure matter, not a patent-infringement action.

What is Potter v. Valeant Pharmaceuticals International, Inc.?

Potter was brought on behalf of investors who purchased or acquired Valeant publicly traded securities during the company’s rapid growth and subsequent disclosure crisis.

The complaint alleged violations of:

• Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5;
• Section 20(a) of the Exchange Act, asserting control-person liability against senior executives and directors; and
• Related federal securities-law provisions based on alleged material misstatements and omissions.

The claims focused on whether Valeant and its executives misled investors about the company’s operating model, sales practices, accounting, pharmacy relationships, and regulatory exposure.

Case identification

Item	Information
Case	Potter v. Valeant Pharmaceuticals International, Inc.
Case number	3:15-cv-07658
Court	U.S. District Court for the District of New Jersey
Filing year	2015
Litigation type	Securities class action
Principal company	Valeant Pharmaceuticals International, Inc., later Bausch Health Companies Inc.
Core securities	Valeant common stock and other publicly traded securities
Related proceeding	In re Valeant Pharmaceuticals International, Inc. Securities Litigation
Principal subject	Alleged securities fraud and investor losses
Patent claims	None identified in the case

What allegations did investors make against Valeant?

Investors alleged that Valeant concealed or misstated information that was material to the company’s valuation.

Philidor and specialty-pharmacy disclosures

A central issue was Valeant’s relationship with Philidor Rx Services, a specialty pharmacy that helped process prescriptions for Valeant products. Investors alleged that Valeant failed to disclose the extent of its control over, or financial relationship with, Philidor.

The litigation examined allegations that:

• Valeant used Philidor to increase or accelerate prescription fulfillment;
• Valeant did not adequately disclose the relationship to investors;
• Philidor’s operations created risks involving reimbursement, prescription processing, and accounting;
• Valeant’s disclosures understated the effect of the relationship on reported revenue; and
• the company lacked adequate internal controls over related-party or affiliated operations.

The issue became public in October 2015 after media reports and investigative disclosures raised questions about Philidor’s business practices and Valeant’s financial reporting.

Revenue recognition and accounting controls

The complaints alleged that Valeant recognized revenue improperly or prematurely and used accounting practices that made the company’s growth appear stronger than its underlying demand.

Investors challenged disclosures concerning:

• inventory held by distributors and pharmacies;
• product returns and reserves;
• revenue timing;
• accounts receivable;
• channel inventory;
• internal accounting controls; and
• the reliability of Valeant’s financial statements.

The claims did not depend solely on whether Valeant’s accounting ultimately violated generally accepted accounting principles. The broader issue was whether Valeant adequately disclosed known risks, unusual sales channels, and weaknesses in its controls.

Drug pricing and acquisition strategy

Valeant’s business model relied heavily on acquiring pharmaceutical assets and raising prices on certain products. Plaintiffs alleged that the company misrepresented the sustainability of its pricing strategy and failed to disclose risks associated with political, regulatory, and payer scrutiny.

The litigation addressed allegations concerning:

• aggressive price increases;
• the sustainability of revenue growth;
• dependence on acquisitions;
• debt-funded expansion;
• pressure from insurers and pharmacy-benefit managers; and
• regulatory and political scrutiny of pharmaceutical pricing.

Debt and business-model risks

Valeant’s expansion generated substantial debt. Plaintiffs alleged that company disclosures did not adequately communicate the risks created by:

• high leverage;
• dependence on continued revenue growth;
• integration of acquired businesses;
• reduced access to capital markets;
• potential covenant pressure; and
• the company’s ability to refinance or service debt.

As Valeant’s stock price declined, the debt and acquisition model became a major part of the alleged corrective disclosures.

What caused Valeant’s stock-price decline?

Valeant’s stock-price collapse occurred through a series of disclosures rather than one event.

Period	Event or development	Litigation significance
2015	Valeant continued to face scrutiny over pricing, acquisitions, debt, and accounting	Increased investor concern about the company’s growth model
October 2015	Public reports raised questions about Philidor and Valeant’s relationship with the pharmacy	Triggered major share-price declines and expanded securities claims
Late 2015	Valeant disclosed additional information concerning revenue, accounting, and operational issues	Plaintiffs characterized disclosures as corrective
2016	Valeant revised guidance and faced continuing regulatory and investor scrutiny	Expanded alleged damages and loss causation arguments
2016-2018	Related securities actions were consolidated and litigated	Pleading, class-certification, discovery, and settlement proceedings followed
2019-2021	Parties pursued a large-scale settlement	Claims were resolved without a merits trial

The plaintiffs’ theory was that Valeant’s alleged misstatements artificially inflated the value of its securities. When corrective information entered the market, the inflation allegedly dissipated, causing investor losses.

What was the procedural history of the case?

Potter was one of several securities cases filed after the 2015 collapse in Valeant’s market value. The District of New Jersey consolidated related actions under the Valeant securities-litigation caption.

Consolidation and amended pleadings

The consolidated litigation covered allegations by investors who purchased Valeant securities during the relevant class period. Plaintiffs filed consolidated and amended complaints that expanded the factual allegations concerning:

• Valeant’s accounting;
• Philidor;
• drug pricing;
• revenue recognition;
• internal controls;
• executive compensation and incentives; and
• public statements made in SEC filings, earnings releases, investor presentations, and conference calls.

The defendants included Valeant, certain current and former officers and directors, and other parties associated with the company’s public disclosures.

Motions to dismiss

Valeant and individual defendants challenged the complaints under the heightened pleading requirements applicable to federal securities-fraud claims.

The principal issues included:

• whether plaintiffs identified specific false or misleading statements;
• whether the complaint alleged facts showing defendants’ knowledge or recklessness;
• whether the alleged misstatements were material;
• whether plaintiffs established a connection between the disclosures and stock-price losses;
• whether the complaint adequately pleaded loss causation; and
• whether claims against individual defendants were sufficiently particularized.

Securities cases under the Private Securities Litigation Reform Act require plaintiffs to plead falsity and scienter with particularity. That standard was central to the motion practice.

Class certification and discovery

The litigation proceeded as a proposed investor class action. Class certification required plaintiffs to establish, among other elements, that common issues predominated and that the named plaintiffs and proposed counsel could adequately represent the class.

Discovery focused on:

• internal Valeant communications;
• Philidor agreements and operating records;
• accounting and revenue-recognition practices;
• communications with auditors;
• board and committee materials;
• SEC filings and earnings disclosures;
• pricing and reimbursement practices; and
• the timing and market effect of corrective disclosures.

The large volume of related investor claims increased the settlement value and reduced the likelihood that the case would be resolved through a single plaintiff-specific proceeding.

Was the Potter case resolved by settlement?

Yes. The Valeant securities litigation was resolved through a reported settlement of approximately $1.21 billion.

The settlement addressed claims arising from alleged misrepresentations and omissions concerning Valeant’s business and financial condition. It avoided a trial on liability, scienter, loss causation, damages, and the defenses asserted by Valeant and the individual defendants.

Settlement characteristics

Issue	Analysis
Settlement amount	Approximately $1.21 billion, as publicly reported
Resolution	Class-action settlement
Admission of liability	Settlement does not constitute a trial finding of liability
Class members	Investors meeting the court-approved purchase or acquisition criteria
Allocation	Based on recognized loss calculations under the settlement plan
Release	Released claims covered by the court-approved settlement
Trial outcome	No merits verdict against Valeant reported
Business impact	Material financial exposure, offset in part by insurance and other sources depending on the settlement structure

The settlement amount was significant relative to Valeant’s financial condition during the litigation period. It also reflected the combination of alleged damages, the number of investors, the company’s litigation risk, and the cost and duration of continued discovery and trial preparation.

What was the financial exposure for Valeant?

The principal financial exposure was the securities settlement, together with defense costs, other litigation, regulatory investigations, debt pressure, and restructuring expenses.

Valeant’s exposure extended beyond the Potter litigation because the same underlying events generated multiple proceedings, including:

• shareholder securities actions;
• derivative claims;
• regulatory inquiries;
• accounting and disclosure investigations;
• pharmacy-related investigations;
• consumer and payer disputes; and
• claims involving former executives and other counterparties.

The securities settlement did not eliminate every potential claim arising from Valeant’s conduct. Its effect depended on the definition of the settlement class and the scope of the released claims.

The company’s broader financial position also changed materially. Valeant later changed its corporate name to Bausch Health Companies Inc. and pursued asset sales, debt reduction, and business restructuring. Those actions affected the company’s ability to fund litigation, settle claims, and preserve operating assets.

Did Potter involve Paragraph IV challenges or pharmaceutical patent litigation?

No. Potter was not a Hatch-Waxman patent case and did not involve an Abbreviated New Drug Application, Paragraph IV certification, biosimilar application, Orange Book patent listing, or patent-infringement claim.

Patent and regulatory relevance

Topic	Potter status
Orange Book patent litigation	Not at issue
Paragraph IV challenge	Not at issue
ANDA litigation	Not at issue
Biosimilar litigation	Not at issue
Formulation patents	Not at issue
Method-of-use patents	Not at issue
Manufacturing patents	Not at issue
FDA approval dispute	Not the principal claim
SEC disclosure and securities law	Central to the case

The case may have involved commercial products subject to FDA regulation, pricing scrutiny, and reimbursement rules, but those facts were relevant to alleged investor disclosures rather than patent enforceability.

What companies challenged Valeant in the litigation?

The primary challengers were investors and institutional shareholders, not generic-drug companies or biosimilar manufacturers.

The litigation was driven by alleged securities losses following public disclosures about Valeant’s business practices. Competitors, generic manufacturers, and pharmaceutical licensors were not the principal plaintiffs in Potter.

This distinction matters for transaction and competitive analysis. A securities settlement does not determine:

• whether a Valeant product is patent protected;
• whether a generic manufacturer can launch;
• whether a product has remaining regulatory exclusivity;
• whether a patent is valid or enforceable; or
• whether a competitor has freedom to operate.

How strong was Valeant’s patent estate in relation to Potter?

Potter provides no adjudicated assessment of Valeant’s patent estate.

The case did not determine:

• patent validity;
• patent enforceability;
• patent term;
• Orange Book listing status;
• exclusivity for any active ingredient;
• formulation protection;
• manufacturing-process protection; or
• generic-entry timing.

Any patent-strength analysis must be conducted separately by product and jurisdiction. Valeant’s portfolio included branded medicines, acquired assets, specialty products, and products subject to varying levels of patent, regulatory, reimbursement, and commercial protection. The securities claims concerned the accuracy of public disclosures about the company, not the legal strength of individual patents.

What litigation risks did the case create for Valeant executives and directors?

The case created potential control-person and individual-liability exposure for officers and directors who signed public filings, participated in earnings calls, or allegedly knew about undisclosed risks.

The main individual-defense issues were:

• whether each defendant made or substantially participated in the challenged statements;
• whether each defendant acted with scienter;
• whether directors exercised control over the persons alleged to have violated the securities laws;
• whether the challenged statements were protected forward-looking statements; and
• whether plaintiffs could connect each individual defendant to the alleged loss.

Individual defendants often seek dismissal on the basis that generalized allegations against a company do not establish personal liability. Plaintiffs respond by relying on executive access, internal reports, board materials, public statements, compensation incentives, and the timing of disclosures.

What does the case mean for pharmaceutical companies?

The case illustrates litigation risk created when a pharmaceutical company’s operating model depends on aggressive pricing, acquisitions, unusual distribution channels, and complex revenue recognition.

The principal corporate-governance lessons are operational rather than patent-specific:

1. Public disclosures must explain material relationships with specialty pharmacies, distributors, and affiliated entities.
2. Revenue-recognition controls must address channel inventory, returns, reserves, and third-party reimbursement.
3. Acquisition-driven growth disclosures must identify integration, leverage, and sustainability risks.
4. Drug-pricing disclosures must address political, payer, regulatory, and market-access risks.
5. Board oversight records may become central evidence in securities litigation.
6. Corrective disclosures can generate substantial damages when they reveal previously undisclosed weaknesses in the business model.

For pharmaceutical companies, the litigation also shows that patent ownership does not eliminate securities exposure. A company can hold enforceable patents and still face major liability if it misstates revenue, compliance controls, distribution arrangements, or commercial risks.

What is the current litigation status of Potter?

The Potter litigation was resolved through the Valeant securities class-action settlement process rather than by a reported merits judgment after trial.

The operative litigation was the consolidated Valeant securities action. The settlement framework governed claims, class participation, notices, objections, exclusions, and distribution of the settlement fund. The original Potter caption is therefore best understood as an initiating case within the larger consolidated proceeding.

The case has no reported impact on pharmaceutical patent validity, FDA exclusivity, generic launch timing, or biosimilar competition.

Key Takeaways

• Potter v. Valeant was a District of New Jersey securities class action filed in 2015.
• The case concerned alleged misrepresentations about Philidor, revenue recognition, drug pricing, accounting controls, acquisitions, and debt.
• The litigation was consolidated with related Valeant investor actions.
• The case was resolved through a reported settlement of approximately $1.21 billion.
• There was no reported merits trial finding that Valeant or its executives violated the securities laws.
• Potter did not involve Orange Book patents, Paragraph IV certifications, ANDA litigation, biosimilars, or formulation patents.
• The case created material financial and governance exposure for Valeant and its former executives and directors.
• Patent, regulatory-exclusivity, and generic-entry questions must be analyzed separately by product.

FAQs About Potter v. Valeant Pharmaceuticals

Was Potter v. Valeant a patent case?

No. It was a securities-fraud class action involving alleged misstatements and omissions to investors.

What was the Valeant Philidor litigation about?

The Philidor-related allegations concerned Valeant’s disclosures about its relationship with the specialty pharmacy, prescription processing, revenue recognition, and internal controls.

Did Valeant admit wrongdoing in the settlement?

A settlement resolves claims without a trial determination of liability. The settlement should not be treated as an adjudicated finding that Valeant committed securities fraud.

Did the Valeant settlement compensate all shareholders?

Only investors meeting the court-approved class definition and submitting valid claims were eligible for distributions. Payments depended on recognized losses under the settlement plan.

Did the case affect generic drug launch dates?

No. The case did not adjudicate patent terms, FDA exclusivity, Orange Book listings, or generic-entry rights.

References

1. U.S. District Court for the District of New Jersey. (2015-2021). Potter v. Valeant Pharmaceuticals International, Inc., No. 3:15-cv-07658. Court docket and filings.

2. U.S. District Court for the District of New Jersey. (2015-2021). In re Valeant Pharmaceuticals International, Inc. Securities Litigation, No. 3:15-cv-07658. Consolidated docket and settlement filings.

3. U.S. Securities and Exchange Commission. (1934). Securities Exchange Act of 1934, §§ 10(b) and 20(a), 15 U.S.C. §§ 78j(b), 78t(a).

4. U.S. Securities and Exchange Commission. (2000). Securities Exchange Act Rule 10b-5, 17 C.F.R. § 240.10b-5.

5. U.S. Congress. (1995). Private Securities Litigation Reform Act of 1995, Pub. L. No. 104-67, 109 Stat. 737.